On July 30, 2019, TrialSite News covered in depth the complex history of Errant Gene Therapeutics and the actions that led to its present court case, Case 150856/2017, Errant Gene Therapeutics vs. Sloan Kettering. At the time of this publication, the small, Chicago-based biotech venture Errant Gene Therapeutics, LLC (EGT) was engaged in a court battle against a well-funded biotech called Bluebird Bio and a venture capital firm known as Third Rock Ventures. The allegations included breach of contract, tortious business interference, and fraud. We summarized publicly available information, including court records; and in less than a month, our article has received over 1500 views and numerous communications from those interested.
Even Patrick Girondi, founder of EGT, commented on the article, saying, “I really appreciate the story. It’s amazing what’s public. Unfortunately, in many ways, the industry has been highjacked by greed. Mine is only one of many stories.” TrialSite News feels honored to have received this appreciation from Girondi regarding our portrayal of what appears to be a raw and true manifestation of capitalistic rapacity and its ripple effects.
Dedicated to tra...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).